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ABSTRACT 
ELAINE WALLIN SMITH: Exploration of Thiol-Michael Addition Bioconjugation to 
Extend Polymers of a Protein-Based Hydrogel 
(Under the direction of Dr. Susan Pedigo) 
 
 
 
Hydrogels have been explored for many biomedical applications, including 
targeted, in situ drug delivery to avoid the negative side effects associated with systemic 
delivery. In our work, we are exploiting the high affinity, calcium-dependent binding 
between calmodulin and its target peptides to create a biomaterial for in situ, extracellular 
drug delivery. Genes were engineered to make two protomers, Calmodulin Collagen-Like 
Protein (CCLP) and Peptide Collagen-Like Protein (PCLP), that will spontaneously self-
assemble in situ due to the high Ca2+ concentration in the extracellular space and provide 
tunable, targeted drug delivery in a biocompatible hydrogel. One important factor that 
would dictate the potential utility and application of this hydrogel is the geometry of the 
protomers involved. Longer polymers have higher levels of entanglement and thus form 
gels with greater integrity. We used Thiol-Michael addition chemistry to bioconjugate 
our protomers with polyethylene glycol (PEG) crosslinkers in order to fine-tune the 
physical properties of the resultant hydrogel, such as elasticity and viscosity. We took 
advantage of the base-catalyzed Thiol-Michael addition mechanism and performed 
reactions between the cysteine residues of our genetically-engineered protomers and both 
divinyl sulfone and maleimide-based PEG crosslinking reagents. We studied the extent of 
bioconjugation and the effects of factors including concentration of reducing agent and 
	 vi 
denaturant, temperature, identity of the Michael acceptor, and the ratio of crosslinker to 
protein. Results were assayed by gel electrophoresis. We found that maleimide-PEG 
reagents are far more reactive than those based on divinyl sulfone, and at a lower pH. 
Additionally, bioconjugation is most promoted by the presence of 1 mM TCEP (reducing 
agent). Temperature and urea (denaturant) do not have significant effects on the reaction. 
The three constructs we tested were all modifiable, but we see particular potential in our 
CCLP Bis-Cysteine construct because it is capable of multiple bioconjugation reactions 
due to its bifunctional nature. The chemistry described here can be used to fine-tune the 
physical properties of the hydrogels formed by our protomers for a wide array of 
applications. 
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CHAPTER 1 
INTRODUCTION 
 Currently, significant effort is being devoted to specific targeting of 
pharmaceutics to affected tissues or physiological systems. One approach is in situ drug 
delivery in which a drug depot is embedded in specific tissues to allow delivery at the 
intended site rather than systemic distribution characteristic of oral or intravenous 
delivery. In situ drug delivery systems are advantageous because they limit pleiotropic 
effects and release the drug only where it is needed most. In situ drug delivery is enabled 
by a number of techniques including subcutaneous slow compression hypodermics which 
require surgery to implant, and depending on the site of the drug reservoir, surgery to 
refill. The work described herein is directed toward an injectable, protein-based gel that 
would be resident at the site where it is needed without associated mechanical devices or 
surgical intervention. The protein components will be covalently modified by drug such 
that it delivers drug in situ directly at the site where it is needed. 
Hydrogels are composed of three-dimensional polymeric networks that hold large 
quantities of water. Many over-the-counter products are hydrogels intended for external 
use such as cosmetics and topical ointment and lotions.1 The use of hydrogels for in situ 
drug delivery has been well established and in active use for approximately 15 years, and 
are traditionally composed of synthetic components such as polyethylene glycol (PEG). 
Protein- and carbohydrate-based hydrogels are of interest because natural components 
increase their biocompatibility, degradation, and excretion. Such “natural” hydrogels 
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have been explored for some time in a wide range of in vivo uses including seeding cell 
growth in artificial tissues2 and dendrimer formation for drug delivery systems for 
treatment of inflammation.3 Our project focuses on a novel hydrogel that is based on the 
specific interaction between the protein calmodulin and a particular peptide that it binds 
with high affinity in vivo. Since both protein components are natural proteins found in 
humans, we expect our engineered proteins will be biocompatible as well. Their 
degradation and excretion should occur through normal physiological mechanisms. 
Further, we have designed the components of our system to provide the flexibility of 
forming a protein-only hydrogel or a hybrid hydrogel composed of protein and synthetic 
components. A specific feature of this calmodulin-peptide hydrogel is that calcium in the 
extracellular space in vivo will promote the association of the calmodulin- and peptide- 
based components into a physical hydrogel, which will serve as a drug depot. The gel can 
be injected at the site of inflammation to provide a depot of drug to be released by 
hydrolysis reactions in a targeted way. The following section describes the general 
structure of our novel hydrogel, and introduction into inflammation and the drugs we 
intend to deliver in situ.  
 
I. Inflammation and Common Anti-inflammatory Drugs 
Inflammation is a physiological reaction to injury and infection. It is a normal and 
important action that engages cellular machinery to allow tissue repair and destruction of 
pathogens. Because of the ubiquity of inflammatory response, we take over-the-counter 
and prescription drugs to lessen the discomfort of its symptoms. The front line drugs are 
nonsteroidal anti-inflammatory drugs (NSAIDs). They are inexpensive, readily available, 
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and well-studied. Below we will describe chronic inflammation, the disease form of the 
inflammatory response, and the pleiotropic effects of NSAIDs that in situ drug delivery 
systems are developed to avoid.  
 Acute inflammation is part of the body’s natural defense mechanism to address 
injury or infection. Pain, redness, and swelling of affected tissues are all symptoms of 
inflammation; mechanisms to resolve injury and infection include recruitment of 
neutrophils or other granulocytes to affected tissue, and then phagocytosis of damaged 
tissue or infectious agents.4 For our purposes, the two major factors that are the hallmark 
of inflamed tissues are the secretion of proteases and the acidification of tissue.5 In acute 
inflammatory events, acidification recruits the granulocytes, and then the secretion of 
proteases follows, causing the remodeling of the EC collagen network so that normal 
tissue can be rebuilt.6 
 Chronic inflammation is a disease state that is due to the inability of the 
inflammation machinery to resolve the underlying problem. Chronic inflammation is a 
relevant condition to many of us since it is related to osteo- and rheumatoid arthritis3, 
atherosclerosis7, cancer8, 9, inflammatory bowel disease10, endometriosis11, and acute 
conditions such as the formation of surgical adhesions.12 
 NSAIDs are a class of drugs primarily used for pain relief and to treat ubiquitous 
acute and chronic inflammation. Because of their relative safety and long history of 
efficacy, they are the most commonly purchased over-the-counter drug worldwide.13 
Their general mechanism is to work as inhibitors of cyclooxygenases, critical enzymes 
that are necessary to synthesize prostaglandins, thromboxanes, and leukotrienes, 
paracrine hormones that function in specific tissues and under specific physiological 
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states.14 For our purposes, prostaglandins are the main concern. In the inflammatory 
response, they are produced by the damaged tissue and cause local swelling, acidification 
and secretion of collagenases, enzymes that remodel the EC collagen network.15, 16 As 
such, NSAIDs are critical for reducing the pain and tissue remodeling effects of 
inflammation in order to reduce the impact of chronic conditions. NSAIDs are delivered 
almost exclusively orally, and are, therefore, distributed throughout the tissues 
systemically. Since they are absorbed in the intestinal tract, they have particularly 
devastating side effects on the mucosal linings in the stomach and intestine,17 sites where 
normal prostaglandin synthesis ensures the natural regeneration of the mucosal layers to 
prevent damage in the harsh environment of our digestive system. The destructive effects 
in the digestive system lining and the massive dosages required because of systemic 
distribution of these efficacious drugs means that inflammation and its unpleasant side 
effects are inadequately addressed by oral administration of the drug.  
Clearly, inflammation is an important issue to be addressed, and NSAIDs would 
be more potent and less harmful if they were delivered in a targeted way. We envision 
our hydrogel will be injected at the site of inflammation. For example, it could be placed 
in the abdominal cavity to prevent the adhesions that form due to inflammation in 
conditions such as endometriosis, or after surgery. Other applications could include pain 
and inflammation relief due to constrictions or compressions of spinal nerves or cartilage 
damage in synovial joints. Further, targeted, in situ drug delivery systems are particularly 
important when the drug in question is toxic in general circulation, or has low solubility 
in the blood. These factors motivate our interest in developing the calmodulin-peptide 
hydrogel under study here.  
	 5 
Our plan is to modify the hydroxyl and/or amino groups on the protomers in the 
hydrogel with an NSAID via hydrolysable ester linkages to create a responsive, targeted 
drug delivery system. The responsive nature of this hydrogel is based on a variation in 
pH; these ester linkages are increasingly hydrolysable at lower pHs.18 Some sources have 
speculated that inflammation causes a decrease in tissue pH,5 which in turn makes the 
ester linkages more subject to hydrolysis, meaning they are cleaved at a faster rate and 
more drug is released to combat the increase in inflammation. Therefore, this hydrogel 
system is responsive to bodily conditions, providing targeted and tunable treatment of 
inflammation. The affixing of the drug analogue will be done via a propargylation 
reaction followed by a Huisgen 1,3-dipolar cycloaddition. The resulting modification will 
be evaluated through mass spectrometry. 
 
II. Description of the Calmodulin-Peptide Hydrogel 
The motivation for using the calmodulin-peptide interaction as the basis for the 
assembly of the hydrogel is threefold. First, as mentioned above, the protein components 
are present in human physiology, and so we would expect that they would not elicit an 
immune response, as this would be counter-productive to the effect of the drug. Using a 
“natural” hydrogel, such as this one, reduces the risk of adverse reaction because it is 
broken down through naturally occurring enzymes, MMP-1, -8, and -13. Second, 
calmodulin and peptide interact with very high affinity and with high specificity at 1 mM 
calcium levels, the normal extracellular concentration in vivo.19 As such, the environment 
in which the hydrogel is injected will have the necessary calcium to stabilize its structure 
and allow for spontaneous self-assembly in situ. Finally, protein-based drug delivery 
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systems provide precise genetic control over the chemistry of the constructs. For 
example, we altered the genetic sequence of each construct to control factors like the rate 
of hydrolysis and the reactivity of amino acid residues in bioconjugation reactions. 
In this section, first I will describe the salient features of calmodulin and the 
peptide. Second, I will describe how these components are situated into an engineered 
protein context that contains design elements necessary for the assembly of the hydrogel, 
and how they assemble into a hydrogel. Finally, I will show that hydrogel formation is a 
reality. 
  
A. Calmodulin and Peptide 
Calmodulin is a very important intracellular regulatory protein that has been 
extensively studied as recorded in the literature. A quick keyword search of PubMed 
shows 4900 articles on calmodulin in the last 5 years. Its protein chemistry and 
physiological roles are well studied, providing a deep literature base for its use in protein 
engineering. This protein was a clear choice for this biomaterial because it reversibly 
denatures and has high affinity binding with its peptide binding partners.20 It is soluble 
from a dried powder. Its function is unperturbed by treatment in boiling water. This 
remarkable resiliency simplifies purification and, we hypothesize, will allow it to retain 
function after repeated exchanges between aqueous and organic solvents. There is ample 
literature that would direct mutations to modify calcium binding affinity and peptide 
binding affinity,21 possibilities that may be important in the future to broaden the 
properties of the hydrogel to suit a diverse range of purposes. Our hydrogel uses the 
protein sequence for wild type vertebrate calmodulin.  
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A ribbon drawing of the crystal structure of calmodulin is depicted in Figure 1.1 
below. There are 148 amino acids in calmodulin, divided into two distinct globular 
domains separated by a central “helix” segment. The pairs of calcium binding sites in 
each domain are in the EF-hand family (helix-loop-helix). The “loop” contains the amino 
acids responsible for calcium binding (yellow) regions. At the back of each pair of sites is 
a short region of β-sheet. The Kd for calcium binding to calmodulin is ~1 µM in the C-
terminal sites and ~10 µM in the N-terminal sites,22 well below the 1 mM level found in 
the EC-space in vivo.19 
 
Figure 1.1. Ribbon and cartoon 
drawings of calmodulin. A) Ribbon 
drawing of calmodulin.23 The N-domain (Sites 
1 and 2; blue) and the C-domain (Sites 3 and 
4; red) are separated by the central helix. The 
middle of the central helix will lose its helical 
character when it is in solution or in 
equilibrium with binding peptides. The 
calcium binding sites are in yellow. B) 
Schematic that illustrates the exposure of 
hydrophobic surface area at the base of each 
domain (orange crescents) when calcium 
binds. C) Ribbon drawing of the crystal 
structure of calmodulin binding the M13 
peptide (green helix).24 D) Schematic 
representation of calmodulin binding M13 
peptide (green cylinder). (Pedigo Lab 
Archive) 
 
The peptide component of our hydrogel is M13, a 26 amino acid peptide derived 
from skeletal muscle myosin light chain kinase. Its sequence is very basic 
(KRRWKKNFIAVSAANRFKKISSGAL; 5 lysines (K) and 2 arginines (R), and no acidic 
residues) with hydrophobic components tryptophan (W, position 4) and a FIAVSAA 
segment that is strikingly extended and hydrophobic compared to the rest of the 
sequence. It binds calmodulin in the presence of Ca2+ with an affinity < 10 nM and a 1:1 
stoichiometric ratio.25 This high affinity in the presence of calcium is useful because the 
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Ca2+ intrinsically present in the extracellular space will be sufficient to promote hydrogel 
formation.  
 
  B. Engineered Calmodulin and Peptide Protomers 
 The general design of calmodulin and peptide protomers are shown in Table 1.1 
below. CCLP stands for Calmodulin Collagen-Like Protein and PCLP is Peptide 
Collagen-Like Protein. The protomers have repeating units consisting of either 
calmodulin (CaM) or M13, and the collagen-like sequences. Preceding the first repeat in 
each construct is a short segment with a His-Tag sequence (His6) and a thrombin 
cleavage site. These two features at the N-terminus of the protomers allow us to purify 
the protomers with His-Tag Chromatography, and then to cleave off the N-terminal 
segment after His-Tag Chromatography is complete. A C-terminal cysteine residue is 
useful as a site of modification, or for crosslinking of protomers to create dimeric linear 
protomers.  
 
Table 1.1. Schematic of engineered protomers with CaM and M13.  
Name Structure 
CCLP2 
 
PCLP2 
  
CCLP3 
 
PCLP3 
 
CCLP 
Bis-Cys 
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In the Table 1.1 above, the yellow represents a His6 sequence used in HisTag 
purification. The blue X is CaM, whereas the green X is M13. The blue B contains three 
collagen-like cleavable sequences, whereas the green B has only one collagen-like 
cleavable sequence. The SH represents the terminal cysteine residue. 
 Each construct is also engineered to contain collagen-like sequences (CLS) that 
are the sites of hydrolysis by collagenases, proteases that are specific for collagen. The 
collagen-like sequence is GPQG/IWGQ. The slash indicates the cleavage site. Optimizing 
these cleavage events is of active interest in the lab. My colleagues, Hunter Berry and 
Christopher Fox, are currently experimenting on the factors affecting the rate of 
hydrolysis of the protomers and the hydrogel by collagen-specific proteases.  
CCLP2 and PCLP2 are so named because they have 2 repeating units, each 
consisting of their respective protein, CaM or M13, and their collagen-like sequences. 
We redesigned the gene to have 3 repeats instead of two, producing CCLP3 and PCLP3. 
Finally, we made an alternate design of CCLP3 with a cysteine residue on both the C and 
N termini, named CCLP Bis-Cys. The structures of each of these constructs is depicted 
above in Table 1.1, and the detailed properties are below, in Table 1.2.  
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Table 1.2. Detailed properties of the engineered CaM and M13 protomers.  
Name Molecular 
Weight 
(g/mol) 
Extinction 
Coefficient 
(M-1cm-1) 
Relative 
solubility in 
water 
# of 
Active 
Sites 
Residues Isoelectric 
point 
Estimated 
net charge 
at pH 7 
CCLP2 46,216 46,940 good 2 423 pH 4.01 -44.1 
CCLP3 58,675 32,430 requires 
salt 
3 530 pH 3.94 -67 
CCLP 
Bis-
Cys 
58,707 32,430 good 3 530 pH 3.94 -67.1 
PCLP2 18,470 53,200 poor 
(denaturant 
required) 
2 177 pH 11.54 19.6 
PCLP3 19,307 35,420 poor 
(denaturant 
required) 
3 179 pH 11.8 22.6 
 
  
When engineering these new constructs, several interesting features have been 
added. The CCLP Bis-Cys has two cysteines. The second thiol increases the likelihood of 
linear polymerization of the construct. To optimize the reactivity of the sulfhydryl on the 
terminal cysteine, we included an arginine residue next to the terminal cysteine(s) of 
CCLP3 and CCLP Bis-Cys. A basic residue in this position has been shown to increase 
its reactivity in Thiol-Michael addition reactions, which will be discussed in part III of 
this chapter.26 
 The mixture of the CCLP and PCLP protomers produces a gel. Figure 1.2 below 
shows the schematic of the interactions between the PCLP and CCLP protomers to form 
a noncovalent, interlinked gel matrix. Our initial protomers contained only two repeats, 
so the interaction options were few. As mentioned above, we have several iterations of 
	 11 
these constructs with different numbers of CLS sequences, calmodulin and M13 inserts, 
and cysteines. The purpose behind the experiments reported in this thesis is to change the 
properties of the gel by covalently linking the protomers together to increase the total 
number of repeats on each chain. The studies reported here are establishing the chemical 
protocols for these linkage reactions.  
A. B.  
 
Figure 1.2. Hydrogel formation.  
(A) Schematic representing the association of CCLP and PCLP proteins to form a hydrogel in the presence 
of Ca2+. (B) A photographic image of a gel formed from CCLP3 and PCLP3 (10% CCLP3-PCLP3; 10 mM 
Ca2+). 
 
 
 III. Our Experiment 
 The primary objective of this project is to establish the framework for the 
development of an injectable, protein-based hydrogel that self-assembles in situ and 
provides targeted drug delivery of NSAIDs. The component protomers interact to form 
the hydrogel through purely non-covalent interactions. We primarily focused on the 
PCLP3 and CCLP3 protomers because they each have three interaction sites for gel 
formation, and they each have a single cysteine. The immediate goal of the experiments 
in this thesis is to create bioconjugated protein dimers by the use of bifunctional reagents 
including divinyl sulfone – polyethylene glycol (VS-PEG-VS) and maleimide – 
polyethylene glycol (Mal-PEG-Mal). With a Thiol-Michael addition between the 
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protomers and PEG reagents, we are able to double the protomer length and therefore 
double the number of reactive sites, theoretically affecting the physical properties of the 
resultant hydrogel, like elasticity and viscosity. Thus, we would expect that the use of 
PEG spacers between the protomers would affect the physical properties of the resultant 
hydrogel; judicious use of crosslinking agents can allow tailoring of gels to specific uses. 
The physical properties of gels dictate their potential applications. Hydrogels that can 
endure high levels of stress could be placed in a joint, whereas gels with relatively weak 
structural integrity could be used in soft tissues. These same physical properties are 
dictated by the length of the gel’s constituent protomers; longer polymers have higher 
levels of entanglement, which increases the gel’s integrity. 
My focus was developing protocols for modifying our protomers through Thiol-
Michael addition bioconjugation reactions, and determining which conditions best 
promote bioconjugation. To this end, we studied specific factors such as the identity of 
the Michael acceptor, reaction temperature, presence of reducing agent, solution 
conditions (pH and presence of denaturant), and the ratio of bifunctional PEG crosslinker 
to our protomers. While the terminal cysteine residues enable the formation of disulfide-
linked dimers between our constructs, we prefer the bioconjugated dimers because they 
are “permanent” and not subject to reduction, so we maintain reducing conditions in 
order to lessen the formation of the disulfide protein dimer. Thiol-Michael addition 
reactions will be described in the following section.  
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  A. Thiol-Michael Addition 
  “Click” reactions have been characterized as “high yielding, wide in scope,” 
rapid, specific, environmentally friendly, and efficient.27 They are also selective, 
straightforward to perform, create only easily removable byproducts, and occur under 
mild conditions.28 Thiol-Michael addition reactions fall under this broader “click” 
category. Michael addition reactions involve creating new chemical bonds between an 
“enolate-type nucleophile” reacting with an electron-deficient ɑ,β-unsaturated carbonyl.27 
This reaction is robust, but also is associated with an enhanced level of control over the 
chemistry while avoiding formation of “significant side products.”27 Thus, we used 
Thiol-Michael addition click chemistry to crosslink our protomers. 
The Thiol-Michael addition reaction is particularly useful because of the “inherent 
electron density of the S atom” which ensures its reactivity under mild conditions.27 
Figure 1.3 below shows two mechanisms for the formation of the thiolate (Michael 
donor), and then the subsequent reaction with the Michael acceptor. The thiolate serves 
as a nucleophile (and Michael donor), attacking the electrophilic carbon-carbon double 
bond of the Michael acceptor. Cysteine is the only amino acid with a thiol group, thus 
affording selectivity over the position of the reaction site in biochemical reactions. In our 
case, we focused on two different Michael acceptors, vinyl sulfone and maleimide. 
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Figure 1.3. Two mechanisms for thiolate formation and the Thiol-Michael addition 
reaction.  
The reaction can proceed under either a base- or nucleophile-catalyzed mechanism. (A) Base-catalyzed 
thiolate formation. (B) Nucleophile-catalyzed thiolate formation. (C) Thiol-Michael addition mechanism. 
(Figure adapted from Nair, et al.27) 
 
In both the base- and nucleophile- catalyzed mechanisms, the thiol of the terminal 
cysteine residue is deprotonated to become a thiolate anion. The thiolate then serves as a 
nucleophile, attacking the electrophilic carbon-carbon double bond of the Michael 
acceptor (vinyl sulfone or maleimide). This reaction forms a carbon-sulfur bond to form 
our Michael product, the modified protomer.  
The thiolate anion produced is unstable and highly reactive, resulting in efficient 
reaction kinetics.27 The kinetics and yield of the Thiol-Michael addition reaction depend 
on the strength and concentration of the catalyst, the pKa of the thiol, the nature of the 
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electron-withdrawing group on the Michael acceptor, steric hindrance, and the solvent 
polarity and pH.27 At physiological pH, thiols react at least 1 order of magnitude faster 
than amines, so thiolates are the predominant nucleophile and this reaction proceeds 
unimpeded by competition from other nucleophiles.26 
In our case, the Michael donor is the thiol of the protomer’s terminal cysteine 
residue. As demonstrated in Figure 1.4, the pKa of this thiol is slightly above 8. 
Therefore, basic conditions seem intuitive in order to promote deprotonation of the 
cysteine thiol and form the nucleophilic thiolate, however the best reaction pH depends 
on the identity of the Michael acceptor, as detailed below. The thiolate is the strongest 
nucleophile present in the reaction, and it initiates the addition of the anion across the 
Michael acceptor’s electrophilic carbon-carbon double bond. Thiolates are typically 
considered the reactive species in this reaction,26 so the reaction rate is strongly 
dependent on the reaction pH and the thiol pKa. Generally, the reaction rate increases 
with pH because basic conditions result in the formation of more thiolate, the reactive 
species.29  
 
 
Figure 1.4. pKas of various thiols. (Figure adapted from Nair, et al.27)  
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Michael acceptors have electron deficient carbon-carbon double bonds that often 
contain an electron withdrawing group. A variety of Michael acceptors and their relative 
reactivities are depicted in Figure 1.5 below. We initially experimented with various 
Michael acceptors, but we ultimately focused on vinyl sulfones and maleimides because 
of their promising chemistry.  
 
 
 
Figure 1.5. Relative reactivity of various Michael acceptors.  
(Figure adapted from Nair, et al.27) 
 
 
Due to the breadth of Michael acceptors explored in this work, I have compiled 
the structures of these reagents. Table 1.3 introduces the various chemicals discussed 
and/or utilized in our Michael addition reactions. 
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Table 1.3. Michael acceptors and polyethylene glycol reagents. 
Compound 
name 
Structure MW 
Divinyl 
sulfone 
(DVS) 
 
118.15 
g/mol 
Methyl-
vinyl 
sulfone 
(MVS) 
 
106.14 
g/mol 
VS-PEG-
VS 
 
 
~3500 
g/mol 
Mal-PEG-
Mal 
 
 
~3500 
g/mol 
 
Vinyl sulfones are useful because they are more stable in aqueous and alkaline 
solutions as compared to maleimides.30 They react with thiols to form stable thioester 
linkages, reacting especially quickly in basic pH.31 The thioester sulfone bond formed by 
the Thiol-Michael addition with a vinyl sulfone is not easily hydrolysable, making it very 
useful for this type of application.27  
Maleimides are considered the most reactive Michael acceptor. The Maleimide 
carbon-carbon double bond is so reactive because of the associated ring strain and the cis-
conformation of its carbonyl groups.27 They are more reactive at lower pHs, between 6.5-
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7.5,32 which is remarkable because the Michael-addition mechanism involves the 
deprotonation of a cysteine thiol, which has a pKa ~8, as seen in Figure 1.4. Maleimide is 
able to undergo this reaction without either catalyst if in a polar enough solvent.27 
Maleimides undergo Thiol-Michael addition reactions to form succinimide bonds. This 
type of bond is more subject to hydrolysis than the vinyl sulfone thioester bond, but it is 
still widely used for this type of application because of its rapid kinetics and selectivity. 
While these Michael acceptors can be reacted with our protomers by themselves, 
we used PEG (polyethylene glycol) to further lengthen the protomers and make the 
modification more visible via gel electrophoresis and mass spectrometry. Bioconjugation 
with PEG, or PEGylation, is a commonly used approach in the modification of peptides 
because of PEG’s hydrophilicity and low susceptibility to degradation by human 
enzymes.29 Therefore, PEGylation can “dramatically extend the stability and improve the 
pharmacology of biomolecule(s).”29 Due to PEG’s hydrophilicity, it can also increase the 
solubility of its binding partners, which we hope to use to increase the solubility of our 
PCLP construct. PEG can be toxic, however this usually only occurs with higher 
molecular weight PEG and at high doses.33 
The bifunctionality of these Michael acceptors is what makes them so useful to 
us; the reactive groups on either side mean that they can react with two separate 
protomers, which would serve to connect two protomers and thereby double the length, 
doubling the number of active sites and theoretically increasing the structural integrity of 
the resultant hydrogel. 
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Through bioconjugation with these compounds, various modified protomers are 
expected as products. Table 1.4 below shows some of the possible results of these Thiol-
Michael addition reactions.  
Table 1.4. Schematic of possible bioconjugation products. 
Name Structure MW 
g/mol 
Unreacted 
protomer 
(“X”) 
 Protein MW 
Mono-
modified 
protomer 
(“X-PEG”) 
 
Protein 
MW 
+3500 
Biocon-
jugated dimer 
(“X-PEG-X”)  
2* 
(protein 
MW) + 
3500 
CCLP Bis-
Cys with 2 
PEGs 
 
~65,700 
CCLP Bis-
Cys 
bioconjugated 
dimer 
 
~124,400 
CCLP Bis-
Cys 
bioconjugated 
dimer with 
extra PEG 
 
~127,900 
Biocon-
jugated trimer  
~186,600 
 
The purple and blue boxes represent a protomer (CCLP, PCLP, or CCLP Bis-
Cys). The yellow circle represents either VS or Mal, and the green star represents PEG. 
The first three (with the blue boxes) are possible with CCLP3, PCLP3, and CCLP Bis-
Cys. The purple ones that follow only apply to CCLP Bis-Cys because it has two 
cysteines available to react with the PEG reagents. The last figure, “bioconjugated 
trimer,” illustrates that this bifunctionality can link three or more protomers, whereas the 
other constructs are limited to two.  
The Bis-Cys construct is particularly intriguing because the cysteine residues on 
either side mean that it could theoretically form a hydrogel by itself. (This is useful 
	 20 
because of its simplicity and PCLP’s solubility issues.) Because of the cysteine residues 
on either end of the construct, and the two Michael acceptors on VS-PEG-VS and Mal-
PEG-Mal, the reaction could theoretically continue indefinitely because no matter which 
of the two is terminal, the reaction could continue to propagate. Methyl vinyl sulfone 
(MVS) could be used as an end-cap to terminate this chain polymerization reaction. 
Figure 1.6 below depicts the possibility for chain polymerization between CCLP Bis-Cys 
and VS-PEG-VS.  
 
 
 
Figure 1.6. Chain polymerization with CCLP Bis-Cys and Michael acceptor.  
This figure illustrates the potential for chain polymerization between bifunctional CCLP Bis-Cys (blue 
helical structure) and either DVS or bifunctional Maleimide. The last step shows how this reaction could be 
terminated: through the addition of a unifunctional sulfone like Methyl-vinyl sulfone (MVS). Figure by 
Christopher Fox. 
 
These modifications will be visualized through gel electrophoresis. This is 
another reason for the utilization of PEG: modification is more easily monitored when 
3500 g/mol is added than it would be for vinyl sulfone or maleimide alone (~100 g/mol). 
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Chapter 2 of this thesis details the reaction conditions that enabled us to explore these 
chemistries.  
To explore these promising reactions further, we designed a series of experiments 
that examined the impacts of the following variables on the reaction’s efficacy and the 
physical properties of the hydrogel: temperature, identity of Michael acceptor, and the 
presence or absence of TCEP, a reducing agent, and urea, a denaturant. 
The reactivity of the thiol, in our case cysteine, is instrumental in dictating the 
reaction rate and product specificity.27 A “linear correlation” has been found between the 
concentration of thiolate and the rate of the reaction, confirming the thiolate’s role as the 
reactive species.29 Researchers also emphasize the connection between the concentration 
of thiolate and the rate of the reaction, stating that the thiolate concentration has the 
largest effect on the reaction rate.29 The concentration of thiolate depends on its pKa, 
which can be manipulated by altering its electrostatic environment. Positively charged 
residues nearby the cysteine have been found to decrease the thiol’s pKa and thus 
increase the rate of the Thiol-Michael addition reaction. For each positive charge, the pKa 
is decreased approximately 0.2 units. Negatively charged residues showed the opposite 
trend. This pKa shift promotes deprotonation of the thiol, and is often induced by 
“electrostatic interactions with neighboring inonizable amino acids and/or polar 
residues.”29 They found that the number of positive charges affects the reaction rate more 
than the charge’s position. This positive charge is thought to influence the transition 
energy and thus kinetics of the reaction. 
Using this information, we modified the gene design of CCLP to include an 
arginine residue near the terminal cysteine(s) on CCLP3 and CCLP Bis-Cys. By 
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modifying our gene, we are partaking in rational peptide design to improve the kinetics 
and selectivity of our reaction.29 Therefore, we can also design an experiment comparing 
the reactivities of CCLP3 and CCLP2, with and without an arginine residue next to the 
cysteine, to compare the effects of this difference in thiol pKa.  
My focus was on exploring factors that influence the extent of bioconjugation. 
Manipulating the reaction time and ratio of the various components would provide a 
range of products of varying lengths, viewable by gel electrophoresis and mass 
spectrometry. Once the conditions that best promote the formation of the bioconjugated 
dimer are uncovered, we will create a hydrogel with these bioconjugated protomers and 
use microrheological techniques to examine how its physical properties differ from a 
hydrogel composed of un-modified protomers. Ultimately, these varying lengths due to 
various extents of modification would produce hydrogels with differing physical 
properties, and thus, potentially different applications.  
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CHAPTER 2 
MATERIALS AND METHODS 
 I. Gene Design 
In order to create the hydrogel, we first had to design genes to synthesize CCLP 
and PCLP. We designed a gene with calmodulin or M13 peptide, respectively, collagen-
like sequences for hydrolysis, and histidine residues to allow for purification via His-Tag 
Chromatography as described in the Introduction and Table 1.1 above. Recombinant 
plasmids were synthesized by Genscript. Genes were sequenced to confirm they were 
correct. Via transformation, we created both maintenance (DH5!) and expression 
(BL21(DE3)) cell lines, and froze them as glycerol-containing cell stocks. The plasmid 
has a kanamycin-resistance gene to select for bacteria that have been transformed.  
 
 II. Expression and Purification 
Sterile LB Agar plates were prepared with 30 µg/mL kanamycin, then inoculated 
with CCLP or PCLP BL21(DE3) by streaking of the frozen cell stocks, and were grown 
overnight. An overnight liquid culture was then prepared by picking a single colony from 
the plate and inoculating a 50 mL liquid LB culture with kanamycin added. A 5 mL 
volume of this culture was used to inoculate a 1 L liquid culture with 50 mL 1 M 
potassium phosphate at pH 7.4 with kanamycin added. After growing cells to midlog 
stage at 37°C, expression of the protein was induced via the addition of 2 mL of 0.4 M 
IPTG. CCLP continues at 37°C, while PCLP is induced at room temperature. The 
	 24 
bacterial cells are allowed to grow post-induction for 5 hours (CCLP) or 18 hours 
(PCLP), at which time the cells are harvested by centrifugation. The supernatant is then 
decanted, then cells are resuspended in 20 mM HEPES, 100 mM KCl, pH 7.4, and then 
frozen overnight. The cells are then thawed and sonicated in order to lyse them, then the 
contents are centrifuged. After centrifugation, the supernatant and the pellet are 
separated. CCLP constructs are soluble and are in the supernatant fraction. PCLP 
constructs are not soluble and are in the pellet fraction. At this point, their purification 
procedures differ and will be described sequentially.  
CCLP, a soluble protein, is present in the supernatant after this step. Calcium is 
added to the supernatant, and then it is heated to 80°C for 10 minutes, cooled, and 
centrifuged. This step causes most bacterial proteins to precipitate and to pellet. In later 
preparations, a protease inhibitor cocktail was added. CCLP is then dialyzed into a high 
calcium, low salt buffer (Buffer A) for Hydrophobic Interaction Chromatography for 
purification in the next step.  
After the expression step, PCLP is present in the pellet. To remove bacterial 
membrane components from the pellet, we use a series of Triton X-100 washes to further 
purify the PCLP, which remains in the pellet. The pellet is then dialyzed in His-Tag 
Binding Buffer with urea added to solubilize the protein for purification in the next step. 
For PCLP, we use His-Tag Chromatography because its low solubility means that it will 
not allow for Hydrophobic Interaction Chromatography. For CCLP, we use Hydrophobic 
Interaction Chromatography because we need a reducing agent present which is 
incompatible with the His-Tag column. Samples are taken at each step and assayed using 
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a 17% polyacrylamide gel (SDS-PAGE) to visualize the purification process of each 
protein.  
We confirm the presence of our purified protein in specific fractions via UV-Vis 
spectroscopy, then prepare the CCLP-containing samples for lyophilization by dialyzing 
them with water. The lyophilization process turns the purified CCLP into a solid, which 
is a more stable form for storage. To prepare for lyophilization while also keeping CCLP 
soluble, we use ammonium bicarbonate (NH4HCO3) in our buffers. During 
lyophilization, the ammonium bicarbonate evaporates, and therefore does not affect the 
mass of the solid protein. It served as a completely volatile salt and also as a pH buffer, 
enabling us to get pure, solid CCLP. 
PCLP is dialyzed into a buffer containing 6 M urea, and then aliquoted and 
frozen. 
 
III. Maintaining Reducing Conditions 
Because the Thiol-Michael addition involves the terminal cysteine, it is important 
that our protein’s sulfhydryl groups stay reduced so they are available to react. We 
maintained anoxic conditions during our experiments. We bubbled in argon to our 
reaction buffers in order to exclude O2 and maintain anoxic conditions. Throughout the 
preparation of the protein, the proteins are kept in solution with 1 mM dithiothreitol 
(DTT), a reducing agent. While we ran an experiment examining the impact of another 
reducing agent, Tris(2-carboxyethyl)phosphine (TCEP), on the Thiol-Michael addition 
reactions, the default reaction condition was 1 mM TCEP in order to increase the 
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proportion of reactive sulfhydryls. More information about the reducing agents is 
available in Appendix D. 
 
 IV. Thiol-Michael Addition Reactions 
We pulled from literature and utilized trial and error to settle on an effective 
protocol for performing the Thiol-Michael addition reactions. The active species is a 
thiolate, so the cysteine thiol must be deprotonated to a thiolate through either a base- or 
nucleophile-catalyzed mechanism. For the vinyl sulfone reactions, we used a 0.3 M 
triethanolamine (TEOA) buffer to promote the base-catalyzed mechanism. Maleimide is 
so reactive that it does not need basic conditions when the reaction is done in a polar 
solvent (water)27. While our actual attempted experiments utilize the base-catalyzed 
thiolate formation, we also explored the nucleophile-catalyzed mechanism, using PPY (4-
pyrrolidinopyridine) as the nucleophile. We found no significant difference in the results 
of bioconjugation between the two mechanisms (see Appendix B). The contents and pH 
of the four buffers utilized in these reactions are detailed in Table 2.1 below.  
 
Table 2.1. Contents of the various buffers used in the Thiol-Michael addition reactions. 
Buffer pH Concentration 
TEOA/KH2PO4 
Concentration 
NaCl 
Concentration 
NaN3 (w/v) 
Concentration 
urea 
1 8.5 0.3 M TEOA 100 mM 0.05% -  
2 8.5 0.3 M TEOA 100 mM 0.05% 6 M 
3 6.5 0.3 M KH2PO4 100 mM 0.05% -  
4 6.5 0.3 M KH2PO4 100 mM 0.05% 6 M 
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The high pH buffers, 1 and 2, were used in the VS-PEG-VS reactions because 
vinyl sulfones are more reactive at basic pHs.27 TEOA serves as both a buffer and a base 
in buffer 1 and 2. Buffers 3 and 4, at pH 6.5, were used for the Mal-PEG-Mal reactions 
because maleimides are more reactive at lower pHs.27 KH2PO4 is used as a buffer. 
Experimenting with the PCLP construct necessitates the use of buffers with 6 M urea, 
and we also used these buffers to explore the effect of a denaturant on the extent of 
bioconjugation. Sodium azide was used to prevent microbial growth.  
The Michael-addition reactions were between the cysteine thiol of our protomers 
and the Michael acceptors already bioconjugated to PEG (VS-PEG-VS and Mal-PEG-
Mal). We investigated three of our constructs: PCLP3, CCLP3, and CCLP Bis-Cys. Each 
coupling reaction was done in a small vial. After weighing out the solid protein, we 
solubilized it in the appropriate, degassed buffer, then added TCEP, then the Michael 
acceptor. They were left stirring for 1 day, with samples taken at the following time 
points: 0 hours, 0.5 hours, 1 hour, 2 hours, and 24 hours. At each of the time points, 10 
µL samples were taken and then quenched with 10 µL of 2x SDS-PAGE reducing 
loading buffer. In order to more clearly visualize the results on the gel, samples were 
diluted to a final CCLP3 concentration of 25 µM before loading 2.5 µL per lane.  
Each reaction series, including the variables tested, is detailed in the Table 2.2 
below. “+” means the component was present in the reaction, “-” means it was absent, 
“c” means it was kept constant in each reaction of the series, and “*” means it was the 
independent variable of the reaction. Details of each experimental setup can be found in 
Appendix C. 
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Table 2.2. Matrix depicting Thiol-Michael reaction conditions. 
Reaction 
Component 
A B C D E F G H Ia Ib J K 
VS-PEG-
VS 
+ + + + - - - - + - + - 
diMal-PEG - - - - + + + + - + - + 
Buffer 1 1 1, 2 1 3 3 3, 4 3 1 3 2 4 
TCEP * + + + * + + + + + + + 
Temp c * c c c * c c c c c c 
Urea - - * - - - * - - - + + 
Ratio of 
reactants 
c c c * c c c * c c * * 
 
 
We utilized SDS-PAGE for the qualitative comparison of the band density at the 
distances corresponding to the different outcomes of bioconjugation. By using 
electrophoresis, we were able to visualize the relative band density and make conclusions 
regarding the impact of each variable, and suggest which conditions best promote 
bioconjugation. 
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CHAPTER 3 
RESULTS 
I. Expression and Purification of Constructs 
Genes for proteins were transcribed and recombinant proteins were expressed 
from cultures of transformed E. coli cell lines. Figure 3.1 shows SDS-PAGE analysis of 
the fractions from the expression of CCLP constructs. The Molecular Weight (MW) 
standard (left lane) allows estimation of the MW of each expressed construct based on its 
migration in the gel. Table 3.1 compares the MW based on the gene sequence (Actual) to 
the estimated MW (Apparent) for each of the constructs. 
A.   B.    C.  
                         (1)            (2)                       (1)       (2)                           (1)      (2) 
Figure 3.1. Expression of CCLP constructs.  
SDS-PAGE analysis expression (lane 1) and soluble supernatant (lane 2) of CCLP2 (A), CCLP3 (B) and 
CCLP3-Bis-Cys (C) are shown. 
 
The CCLP constructs were clearly overexpressed as witnessed by the prominent 
band in lanes 1 in Figures 3.1 A-C. In Figures 3.1 A, B and C, lane 2 shows the 
	 30 
supernatant after centrifugation of the material in lane 1. The fact that the expressed 
protein appears in the supernatant illustrates that the protein is soluble in an aqueous 
HEPES/KCl buffer.  
A similar gel illustrating the expression of PCLP2 is shown in Figure 3.2. In 
contrast to the CCLP constructs, the PCLP construct does not appear in the supernatant 
after centrifugation of the sonicated expression culture. This indicates that PCLP2 (and 
PCLP3, data not shown) is not soluble in the aqueous HEPES/KCl buffer. The PCLP 
constructs required 6 M urea to bring the expressed protein into solution (lane 4, Figure 
3.3). Table 3.1 below contains the actual and apparent molecular weights of each of the 
five protein constructs. 
 
 
Figure 3.2. Expression of PCLP2.  
SDS-PAGE analysis expression (lane 1) and supernatant (lane 2) of PCLP2 are shown. 
 
 
Table 3.1. Actual and apparent molecular weights of the proteins under study. 
Construct Actual MW Apparent MW Soluble ? 
CCLP2 46,216 g/mol 46,340 g/mol Yes 
CCLP3 58,675 g/mol 53,950 g/mol Yes 
CCLP3-Bis-Cys 58,707 g/mol 52,970 g/mol Yes 
PCLP2 18,470 g/mol 18,020 g/mol No 
PCLP3 19,307 g/mol 18,408 g/mol No 
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 Proteins were purified using chromatographic methods as noted in Chapter 2, and 
SDS-PAGE analysis of the resultant purified proteins are shown in Figure 3.3. 
Purification of these constructs from the bacterial cultures was successful with >95% 
purity of the working stocks. CCLP2 (lane 1), CCLP3 (lane 2), CCLP3 Bis-Cys (lane 3) 
were purified using Hydrophobic Interaction Chromatography. PCLP3 (lane 4) was 
purified using His-Tag Chromatography using buffers containing 6 M urea. 
 
	 	 	
	 														(1)          (2)  (3)        (4) 
Figure 3.3. SDS-PAGE analysis of purified proteins.  
 
 
 II. Thiol-Michael Addition 
We set out to determine the factors affecting the bioconjugation of both VS-PEG-
VS and Mal-PEG-Mal to our protomers, focusing on the following factors: concentration 
of the reducing agent TCEP, the reaction temperature, the presence or absence of the 
denaturant urea, and the ratio of PEG:Protein. The independent variables and reaction 
conditions are summarized in Table 2.2 in the Methods section, and Appendix C. The 
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results are grouped by the conclusions we drew from them: the variable has no apparent 
effect, the variable has a positive effect, the variable has mixed effects.  
  A. Independent Variables with no Apparent Effect on Bioconjugation 
   1. Urea 
Because steric hindrance of the thiol has been shown to be a major factor in 
Thiol-Michael addition, we wanted to see if our cysteines were sterically hindered at all 
by testing the effect of a denaturant (urea) on the reaction. The impact of urea on the 
extent of bioconjugation between CCLP3 and VS-PEG-VS (part A) and between CCLP3 
and Mal-PEG-Mal (part B) is shown in Figure 3.4. A general inspection of these two 
figures indicates that the presence of urea during bioconjugation of CCLP3 to either of 
the two Michael acceptors was inconsequential in the results of the study. Lane 2 of (A) 
and (B) contains unmodified protomer; the large band ~55 kDa corresponds to 
unmodified CCLP3 (values listed in Tables 1.2 and 1.4). The subsequent lanes show 
multiple bands, indicating that a reaction occurred that produced a material with a higher 
MW than unmodified CCLP3. These higher MW bands represent the bioconjugated 
products; their creation was the goal of our experiments. The band directly above the one 
at ~55 kDa represents the addition of VS-PEG-VS (in the case of 3.4 (A)) or Mal-PEG-
Mal (in the case of 3.4 (B)). This “mono-modified protomer” is represented by “X-PEG” 
to the right of the gels. “X-PEG-X” represents two CCLP3s bioconjugated through two 
separate Thiol-Michael additions to form CCLP-VS-PEG-VS-CCLP (in the case of (A)), 
or CCLP-Mal-PEG-Mal-CCLP (in the case of (B)). We refer to these constructs as the 
“bioconjugated dimer” as it is two CCLPs connected via bioconjugation. The X-PEG-X 
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band is ~120 kDa, which corresponds to the mass of 2*CCLP3 (~117 kDa) plus the mass 
of VS-PEG-VS or Mal-PEG-Mal (both ~3500 Da).  
 In comparing lanes 3-6 (A) and lanes 7-10 (A), one can see that the proportions of 
each band do not differ significantly between the two conditions, 0 M urea and 6 M urea. 
In fact, 6 M urea may even hinder the reaction, as shown in (B). The reactions with 6 M 
urea added (lanes 6-8) have more unmodified protomer (“X” band) than the 0 M reaction 
(lanes 3-5). The 0 M reaction seems to have a larger proportion of the mono-modified 
(“X-PEG”) band. Given the poor quality of this gel, we argue here that there is not a large 
effect from the presence of urea on the fraction of protomers that are bioconjugated. 
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A.      
B.     
Figure 3.4. Urea has no substantial effect on Thiol-Michael addition bioconjugation. 
(A) Effect of urea on bioconjugation of CCLP3 and VS-PEG-VS [Study C]. Lane 1 contains ladder; lane 2 
contains an initial sample of protein; samples were taken at 30 mins, 60 mins, 120 mins, and approximately 
24 hours; lanes 3-6 correspond to Michael addition without urea, lanes 7-10 correspond to Michael addition 
in 6M urea. (B) The impact of urea and on bioconjugation between CCLP3 and Mal-PEG-Mal [Study G]. 
Lane 1 contains ladder; lane 2 contains an initial sample of protein; samples were taken at 30 mins, 60 
mins, 120 mins, and approximately 24 hours; lanes 3-5 correspond to Michael addition without urea and 
with a 2:1 PEG:CCLP3 ratio; lanes 6-8 correspond to Michael addition in 6 M urea. 
   
2. Temperature 
Temperature was the next variable that was tested. In Figure 3.5 (A) and (B), gels 
show the analysis of samples taken at 4 time points for each of three temperatures. The 
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general trend is that increasing the temperature does not result in an increased proportion 
of mono-modified protomer or bioconjugated dimer. However, for the reactions with 
vinyl sulfone as the Michael acceptor (A), there is less protein on the gel overall at 37°C.  
The band corresponding to unmodified CCLP3 certainly decreased between 22°C and 
37°C, but this is not indicative of increased bioconjugation because we do not see a 
corresponding increase in the X-PEG or X-PEG-X bands. It could be that there are very 
large MW species formed that do not enter the gel, or that the protein is being degraded 
by endogenous proteases. 
Another thing of note is that in the vinyl sulfone reaction (Figure 3.5 (A)), time 
dependence is exhibited, especially at lower temperatures. At 8°C, T30 (lane 3 of (A)), the 
modified protein bands are far smaller than they are after the reaction goes overnight 
(Tov, lane 6). Interestingly, this time dependence is only significant in at the lower 
temperature, and only for VS-PEG-VS. In Figure 3.5 (B), the maleimide reaction, the 
proportions of each band largely stay the same between 30 mins and 24 hours. In (B) 
there is also no significant difference between the relative proportion of the bands as a 
function of temperature. 
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A.  
 
B.  
Figure 3.5. Temperature has no clear effect on Thiol-Michael addition bioconjugation. 
(A) depicts the effect of temperature on the VS-PEG-VS and CCLP3 bioconjugation reaction [Study B]. 
Lane 1 contains ladder; lane 2 contains an initial sample of protein; samples were taken at 30 mins, 60 
mins, 120 mins, and approximately 24 hours; lanes 3-6 correspond to Michael addition at 8°C, lanes 7-10 
correspond to Michael addition at 22°C; lanes 11-14 correspond to Michael addition at 37°C. (B) shows the 
varying extents of bioconjugation between Mal-PEG-Mal and CCLP3 as affected by temperature [Study F]. 
Lane 1 contains ladder; lane 2 contains an initial sample of protein; samples were taken at 30 mins, 60 
mins, 120 mins, and approximately 24 hours; lanes 3-6 correspond to Michael addition at 8°C, lanes 7-10 
correspond to Michael addition at 22°C; lanes 11-14 correspond to Michael addition at 37°C. 
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B. Variables with Distinct Positive Effects on Bioconjugation 
   1. TCEP 
Figure 3.6 depicts the impact of reducing agent TCEP (tris(2-carboxyethyl) 
phosphine) on Thiol-Michael addition between VS-PEG-VS and CCLP3 (part A) and 
Mal-PEG-Mal and CCLP3 (part B). In both Figures 3.6 (A) and (B), the band around 55 
kDa represents CCLP3 (MW 58,675) and the band above it represents the mono-
modified protomer (“X-PEG” (~62,000)). The band below 130 kDa represents the 
bioconjugated dimer (“X-PEG-X” (~120,000)). Over half of the CCLP3 was modified, 
but there is still a substantial amount of unmodified protomer, and the bioconjugated 
dimer band is small. Compare the starred lanes (5 and 13) of (A). Based on visual 
inspection, they have a similar total band density, but note that lane 13 (1 mM TCEP) has 
higher MW bands corresponding to “X-PEG” and “X-PEG-X” than does lane 5 (no 
TCEP). This indicates that 1 mM TCEP promotes bioconjugation, presumably by 
increasing the availability of reduced sulfhydryl groups. In Figure 3.6 (B), the effects of 
TCEP are not as positive as seen for the vinyl sulfone acceptor, but it is clear that TCEP 
has no negative impact on bioconjugation with maleimide. When you examine lanes 3-6 
of (B) and compare them to lanes 11-14 of (B), the results look very similar, but the 1 
mM TCEP seems to have slightly more mono-modified protomer (X-PEG). Notice the 
higher MW bands (~ 250 kDa) in the gel in Figure 3.6 A. We do not have an explanation 
for them. They are higher MW than could be formed based on predicted chemistry.  
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A.  
B.  
Figure 3.6. 1 mM TCEP promotes bioconjugation. 
(A) Impact of TCEP on the bioconjugation of CCLP3 and VS-PEG-VS [Study A]. An initial sample was 
not taken for this reaction. Lane 1 contains ladder; samples were taken at 30 mins, 60 mins, 120 mins, and 
approximately 24 hours; lanes 2-5 correspond to Michael addition in the absence of TCEP; lanes 6-9 
correspond to Michael addition in 0.1 mM TCEP; lanes 10-13 correspond to Michael addition in 1 mM 
TCEP. (B) shows the impact of TCEP concentration on the bioconjugation between CCLP3 and Mal-PEG-
Mal [Study E]. Lane 1 contains ladder; lane 2 contains an initial sample of protein; samples were taken at 
30 mins, 60 mins, 120 mins, and approximately 24 hours; lanes 3-6 correspond to Michael addition in the 
absence of TCEP; lanes 7-10 correspond to Michael addition with 0.1 mM TCEP; lanes 11-14 correspond 
to Michael addition with 1 mM TCEP. 
 
 
   2. Identity of Michael Acceptor 
Different Michael acceptors have different reactivities and are better suited to 
different applications, so we wanted to see if maleimide and divinyl sulfone produced 
distinct results or if either seemed better suited to our reaction. By comparing Figure 3.7 
(A) and (B), we see that the reaction with VS-PEG-VS (A) is less reactive than with Mal-
PEG-Mal (B); Maleimide as the Michael acceptor (B) yields a much denser band 
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corresponding to the mono-modified protomer (“X-PEG”) and the bioconjugated dimer 
(“X-PEG-X”). All other variables were constant. When comparing (C) and (D), it is clear 
that the VS-PEG-VS reaction (C) has a greater proportion of unmodified protomer (“X” 
band), and the Mal-PEG-Mal reaction (D) has a greater proportion of both mono-
modified protomer (“X-PEG”) and the bioconjugated dimer (“X-PEG-X”). Because 
every other variable in the reaction was constant, this difference in bioconjugation 
suggests that maleimide is a more reactive Michael acceptor than divinyl sulfone. 
  VS-PEG-VS             Mal-PEG-Mal 
A. B.  
 
   VS-PEG-VS     Mal-PEG-Mal 
C. D.  
Figure 3.7. Maleimide is a more reactive Michael acceptor than divinyl sulfone. 
(A) shows the results of bioconjugation between CCLP3 and VS-PEG-VS [Study A]. Lane 1 contains 
ladder; samples were taken at 30 mins, 60 mins, 120 mins, and approximately 24 hours; lanes 2-5 
correspond to Michael addition in the absence of TCEP; lanes 6-9 correspond to Michael addition in 0.1 
mM TCEP; lanes 10-13 correspond to Michael addition in 1 mM TCEP. (B) shows the reaction between 
CCLP3 and Mal-PEG-Mal [Study E]. The samples were taken in the same way as (A). (C) shows the effect 
of temperature on the reaction between CCLP3 and VS-PEG-VS [Study B]. Lane 1 contains ladder; lane 2 
contains an initial sample of protein; samples were taken at 30 mins, 60 mins, 120 mins, and approximately 
24 hours; lanes 3-6 correspond to Michael addition at 8°C, lanes 7-10 correspond to Michael addition at 
22°C; lanes 11-14 correspond to Michael addition at 37°C. (D) shows temperature’s effect on the 
bioconjugation of CCLP3 and Mal-PEG-Mal [Study F]. Time points were taken in the same manner as (C). 
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C. Independent Variables with Mixed Effects on Bioconjugation 
1. PEG:Protein Ratio 
Figures 3.8 and 3.9 indicate opposite trends in terms of the effect of PEG:Protein 
ratio on the bioconjugation of CCLP3 and PCLP3. For CCLP3 (Figure 3.8), a higher 
proportion of PEG promotes bioconjugation. For PCLP3 (Figure 3.9), a higher proportion 
of protein promotes bioconjugation. 
Figure 3.8 below depicts three gels in which a higher PEG:Protein ratio seems to 
have a positive effect on bioconjugation. (A) and (B) depict the same reaction conditions, 
CCLP3 and VS-PEG-VS, but at different ratios of PEG:CCLP3. There is more 
unmodified protomer (“X” band) in the 1:2 and 1:1 (A) than the 2:1 (B). This 
corresponds with the greater proportion of mono-modified protomer (“X-PEG”) and 
bioconjugated dimer (“X-PEG-X”) caused by the 2:1 PEG:CCLP3 ratio (B). The effect is 
more drastic on the formation of the mono-modified protomer, but there is also more 
bioconjugated dimer formed. In (C), the same effect is shown for CCLP3 with maleimide 
as the Michael acceptor. Comparing lanes 5 and 8 (starred), the T120 time points of the 2:1 
and 1:2 ratios, respectively, we see that the higher amount of PEG in lane 5 results in 
larger bands of X-PEG and X-PEG-X, with a corresponding decrease in the amount of 
unmodified protomer (band “X”). In lane 8, with twice the CCLP3 as PEG, more CCLP3 
is left unreacted (band “X”), and a smaller portion is actually bioconjugated. 
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A. B.   
 
C.  
Figure 3.8. Bioconjugation with PEG and CCLP3 is promoted by a higher PEG:CCLP3 
ratio. (A) depicts the effect on bioconjugation of manipulating the ratio of VS-PEG-VS:CCLP3 [Study D]. 
Lane 1 contains ladder; lane 2 contains an initial sample of protein; samples were taken at 30 mins, 60 
mins, 120 mins, and approximately 24 hours; lanes 3-6 correspond to Michael addition with a 1:1 VS-PEG-
VS:CCLP3 ratio; lanes 7-10 corresponds to the 1:2 VS-PEG-VS:CCLP3 ratio. (B) depicts the same 
reaction conditions as (A) but at a 2:1 PEG:CCLP3 ratio [Study C]. (C) shows the reaction between CCLP3 
and Mal-PEG-Mal at the three different ratios, as labeled above the gel [Study H]. 
 
Figure 3.9 below shows the PCLP3 bioconjugation results that demonstrate the 
benefit of a 1:2 PEG:Protein ratio, contrary to the results in Figure 3.8. In both figures, 
the dark band between 25 kDa and 15 kDa represents unmodified PCLP3 (MW = 19,307 
g/mol). There is a very faint band slightly above 25 kDa which likely corresponds to 
PCLP3 bioconjugated with one PEG. Compared to our other constructs, this was not an 
appreciable modification whatsoever. However, in Figure (B), there is a significant band 
~55 kDa corresponding to the bioconjugated dimer, PCLP-PEG-PCLP (MW ~44,000). 
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The only PCLP3 sample to be appreciably modified was the 1:2 PEG:PCLP3 ratio of (B), 
the maleimide reaction. Further, the bioconjugated dimer (“X-PEG-X”) is present 
seemingly without any mono-modified protomer (“X-PEG”). This is another result 
unique to PCLP3; in all the other reactions, we saw more mono-modified protomer than 
bioconjugated dimer. Additionally, we see that PCLP3 is generally less subject to 
bioconjugation than CCLP3, but can still undergo it. Figure 3.9 is another example of 
maleimide’s higher reactivity as the VS-PEG-VS reaction seems ineffective, but the Mal-
PEG-Mal reaction is able to produce a significant modification. 
A.  
B.  
Figure 3.9. Bioconjugation with PEG and PCLP3 is promoted by a lower PEG:PCLP3 
ratio.  
(A) shows the bioconjugation of PCLP3 with VS-PEG-VS and the effect of altering the PEG:PCLP3 ratio 
[Study J]. Lane 1 contains ladder; lane 2 contains an initial sample of protein; samples were taken at 30 
mins, 60 mins, 120 mins, and approximately 24 hours; lanes 3-6 correspond to a 2:1 PEG:PCLP3 ratio; 
lanes 7-10 correspond to Michael addition with a 1:1 PEG:PCLP3 ratio; lanes 11-14 correspond to a 1:2 
PEG:PCLP3 ratio. (B) shows the bioconjugation of PCLP3 with Mal-PEG-Mal and the effect of altering 
the PEG:PCLP3 ratio [Study K]. Lane 1 contains ladder; lane 2 contains an initial sample of protein; 
samples were taken at 30 mins, 60 mins, 120 mins, and approximately 24 hours; lanes 3-6 correspond to a 
2:1 PEG:PCLP3 ratio; lanes 7-10 correspond to Michael addition with a 1:1 PEG:PCLP3 ratio; lanes 11-14 
correspond to a 1:2 PEG:PCLP3 ratio. 
	 43 
 III. CCLP Bis-Cys 
We applied the results from the CCLP3 bioconjugation experiments to 
modification of the CCLP Bis-Cys construct in order to provide the best possible 
conditions for bioconjugation. In Figure 3.10, the band above 55 kDa (“X”) represents 
CCLP Bis-Cys (MW=58,707 Da). The band above that represents the addition of one 
PEG (“X-PEG” (~62,000 Da)), and the band above that illustrates the reactivity of both 
cysteines of CCLP Bis-Cys: two PEGs were added, forming “PEG-X-PEG” (MW 
~66,000 Da). The band above 100 kDa corresponds with the bioconjugated dimer (“X-
PEG-X” (MW~120,000 Da)). The band below 130 kDa is likely two distinct bands that 
migrated together, representing the addition of 1 or 2 more PEGs (“PEG-X-PEG-X-
(PEG)” (MW~123.5 kDa or ~127 kDa)). Most significantly, the band above 180 kDa 
(“(PEG)-X-PEG-X-PEG-X-(PEG)”) shows that it is possible to bioconjugate 3 CCLPs. It 
represents CCLP-PEG-CCLP-PEG-CCLP (~184,000 Da). The bands above that represent 
the addition of additional PEGs onto the terminal cysteines of CCLP Bis-Cys, PEG-
CCLP-PEG-CCLP-PEG-CCLP (MW ~187.5 kDa) or PEG-CCLP-PEG-CCLP-PEG-
CCLP-PEG (~191 kDa). Any other compound with a molecular weight similar to these or 
above these would have all combined to form those top bands, so we cannot rule out the 
possibility of a 4- or 5- CCLP bioconjugation product. Interestingly, there is not an 
apparent difference between the two Michael acceptors. We do see a slight time 
dependency, as the Tov samples have a higher proportion of the modified protomers and 
less unmodified CCLP Bis-Cys when compared to the T30 samples. 
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Figure 3.10. Bioconjugation of CCLP Bis-Cys. 
Bioconjugation of CCLP Bis-Cys with VS-PEG-VS and Mal-PEG-Mal [Study I]. Lane 1 contains ladder; 
lane 2 contains an initial sample of protein; samples were taken at 30 mins, 60 mins, 120 mins, and 
approximately 24 hours; lanes 3-6 correspond to Michael addition with VS-PEG-VS as the Michael 
acceptor, lanes 7-10 correspond to Michael addition with Mal-PEG-Mal. 
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CHAPTER 4 
DISCUSSION 
As we examined the results from these gels, we qualitatively compared the 
proportion of modified vs. unmodified protomer and determined which variables led to 
the highest proportion of bioconjugation. The Ti lanes contain unmodified protomer at the 
same concentration as protein is present in all of the other lanes, so we can compare other 
lanes with the Ti lane to how much protein has been modified and how much remains 
unmodified. The Discussion will follow the same organization as the Results: part I will 
discuss the variables that had no significant effect, part II will discuss the variables that 
positively impacted bioconjugation, part III will discuss the variable effects of 
manipulating the PEG:Protein ratio, and part IV will discuss the optimization of these 
factors and the promising results of bioconjugation with CCLP Bis-Cys. 
 
 I. Independent Variables with no Apparent Effect on Bioconjugation 
A. Urea 
The kinetics and yield of the base-catalyzed Thiol-Michael addition mechanism 
depend on the steric accessibility of the thiol, so it is important to address the possibility 
that the thiol may be sterically hindered27. We suspected that including urea as a 
denaturant might increase the efficacy of the reaction by decreasing any secondary or 
tertiary structural elements that would decrease the reactivity of the cysteine thiol. 
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However, the results from Figure 3.4 show that urea does not have a significant effect. 
We do see that the proportion of bioconjugated CCLP3 increases over time.  
Figure 3.4, part (B) shows that 6 M urea can even decrease the amount of 
bioconjugation. The unmodified CCLP3 bands in 6 M urea have a higher relative density 
than the ones for 0 M urea. This could be due to an impact on CCLP3 solubility. As a 
denaturant, urea may affect the solubility of CCLP3 by increasing the exposure of 
hydrophobic residues to solution, which may have affected the reaction in unintended 
ways. 
Because urea does not have a noticeable effect on the bioconjugation reactions, 
we concluded that the cysteine sulfhydryl groups were already sufficiently exposed and 
reactive; no denaturant was needed to expose the thiol, so urea had no substantial effect 
on the reaction. The cysteine residues are genetically engineered to be terminal, so it 
makes sense that they would not be very sterically hindered.  
 
B. Temperature 
Increased temperature is generally favored in order to increase the rate of a 
reaction. The increased temperature increases the kinetic energy of the molecules and 
brings them into contact with each other more often, theoretically contributing to an 
increased proportion of bioconjugated protein. Higher temperatures increase the rate of 
reactions by lowering the transition state energy barrier relative to the energies of the 
reactants and products, but our results did not show a significant effect. We anticipated 
that a higher temperature would increase the kinetics and yield of the reaction, but Figure 
3.5 shows that temperature did not have a significant effect on our bioconjugation 
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reactions. Part (A) suggests a slight trend favoring 37°C because there is far less 
unmodified CCLP3, but we do not see the proportions of the higher MW bands 
increasing, and there is an overall decrease in the amount of protein in the samples. As 
such, it is not a strong argument that the temperature has a large impact on the amount of 
modified protein formed. Perhaps an unintended reaction occurred that produced 
concatenated products that are high MW such that they do not appear on the gel. 
Proteolysis is unlikely because we do not see fragments below ~55 kDa that would 
correspond to small pieces of a cleaved protein. Additionally, we do not think it was due 
to protein precipitation, as pellet particulates would likely be soluble in SDS and thus 
appear in the gel. 
In part (B), the temperature effect is even less significant. This is likely due to 
maleimide being more reactive under every condition, so the difference is not apparent; 
the increased reactivity means that the Mal-PEG-Mal reactions do not rely as much on 
other factors such as temperature or TCEP in order to successfully undergo 
bioconjugation.  
The effect of temperature on reaction rate is most apparent at 8°C where there is a 
clear time dependence of the bioconjugation reaction.  
 
 II. Independent Variables that Positively Affect Bioconjugation 
A. TCEP 
Reducing agent is important in this reaction because it increases the proportion of 
reactive sulfhydryl groups available to participate in the Michael addition reaction. The 
reaction rate depends on the concentration of the thiolate27, so if the thiolate is unable to 
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be formed (i.e. the cysteine thiol is taking part in a disulfide linkage), the reaction rate 
and yield will decrease. 
Our results are in accordance with this prediction. We see a clear increase in the 
modified CCLP3 with 1 mM TCEP. The presence of a reducing agent keeps the cysteine 
reduced to a sulfhydryl rather than allowing oxidation to form a disulfide linkage. The 
disulfide linkage does connect two protomers, but it is less stable than the dimer created 
by bioconjugation with PEG. We cannot observe this dimer on the gels in this document, 
because the SDS-PAGE loading buffer contains a reducing agent. Earlier studies in our 
lab showed that <10% of the protein appeared as disulfide-linked dimer, even after 
exposure to oxidizing reaction conditions (data not shown). 
We found that a concentration of 1 mM TCEP was most effective in promoting 
formation of bioconjugated CCLP3-PEG, and the bioconjugated dimer. The low 
concentration of TCEP, 0.1 mM, has decent proportions of modified protein, but not in 
the same quantity as the higher 1 mM concentration. One can see that the absence of 
TCEP produced the least amount of bioconjugated dimer.  
The results from Figure 3.6 part (B) show that it appears that TCEP does not have 
as large of an effect on the Mal-PEG-Mal reaction as it does with VS-PEG-VS. This 
could be because we better maintained reducing conditions while we were performing the 
experiment so TCEP had less of a role to play, or because maleimide is more reactive and 
the conditions matter less. The Ti sample of (B) (CCLP3 without TCEP) has no 
appreciable band around ~120 kDa, indicating that our anoxic conditions are generally 
sufficient to suppress the formation of the CCLP-CCLP disulfide dimer.  
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B. Identity of Michael Acceptor 
From Figure 3.7, we can see that the Mal-PEG-Mal reactions have a dramatically 
increased proportion of modified CCLP3 as compared to the VS-PEG-VS reactions. Both 
the mono-modified protomer (“X-PEG”) band at ~62,000 Da and the bioconjugated 
dimer (“X-PEG-X”) band at ~120 kDa are much larger than observed for any of the vinyl 
sulfone reactions. A majority of the CCLP3 is bioconjugated, while only a small portion 
remains unmodified, illustrating Mal-PEG-Mal’s reactivity. In (B) we can clearly see that 
bioconjugation with Mal-PEG-Mal results in increased modification and a far higher 
proportion of modified CCLP3 than VS-PEG-VS. This increased reactivity is due to the 
high reactivity of maleimide’s carbon-carbon double bond. It is very reactive and 
electrophilic due to the bond angle distortion and ring strain, in addition to the cis 
conformation of its carbonyl groups27. Maleimide’s higher reactivity has been noted in 
other studies27 and is affirmed by our results. The maleimide reactions were interesting 
because it is more reactive despite not having basic or nucleophilic conditions. Instead, 
the thiolate is thought to form through interactions with highly polar solvents27.  
 
III. Independent Variables with Mixed Effects on Bioconjugation 
A. PEG:Protein Ratio 
In Figure 3.8, it is clear that bioconjugation with CCLP3 is more successful at a 
higher PEG:CCLP3 ratio. Comparing the results from (B) with the results from (A), 
which is admittedly difficult because the gel type was not standardized and different 
amount of samples were loaded, you can see that the 2:1 PEG:CCLP3 ratio (B) has a 
higher proportion of bioconjugation. The 1:1 and 1:2 ratio samples of (A) have far over 
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half of the CCLP3 unmodified, as shown by the big band ~55 kDa. Comparatively, the 
2:1 ratio lanes (B) have over half of the CCLP3 modified. These results demonstrate that 
the 2:1 PEG:CCLP3 ratio best promotes formation of the bioconjugated PEG-CCLP 
construct.  
This is contrary to our prediction, because PEG is bifunctional, so one would 
expect that you would need twice the CCLP3 for every PEG, and the expected ratio 
would thus be 1:2 PEG:CCLP3. We believe these results indicate the importance of a 
high concentration of PEG in order to promote the bioconjugation to the mono-modified 
protomer, CCLP3-PEG. The bioconjugated dimer cannot be formed without sufficient 
CCLP3-PEG, so we do not see an increase in the bioconjugated dimer band either, even 
with the 1:2 PEG:CCLP3 ratio. The reaction rate depends on both the concentration of 
the thiolate and concentration of Michael acceptor, so increasing the amount of Michael 
acceptor (Mal-PEG-Mal and VS-PEG-VS) available to react increases the likelihood that 
a thiolate will perform a nucleophilic attack on it and form the bioconjugated product. 
This also suggests that we have a sufficient concentration of thiolate, as increasing the 
[PEG] increases the extent of bioconjugation.  
When you examine the lanes 5 and 8 in particular on (C), there is clearly more 
unmodified CCLP3 with the 1:2 ratio. Again, this indicates that an excess of PEG is best 
for promoting the bioconjugation between CCLP3 and our PEG Michael acceptors. It 
appears that as you increase the ratio in favor of PEG, you see a shift from majority 
unmodified to a majority modified. The effect on the proportion of the bioconjugated 
dimer is less significant. 
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Contrary to the apparent positive effect that a higher PEG:Protein ratio has on 
bioconjugation with CCLP3, the results from PCLP3 were the opposite, as seen in Figure 
3.9. Figure 3.9 shows that PCLP is also subject to bioconjugation with PEG, although it 
happens at a much more appreciable quantity with Mal-PEG-Mal than VS-PEG-VS. In 
both figures, there is a faint band corresponding to the mono-modified protomer. The 
only significant bioconjugation band in the PCLP reactions is at the 1:2 PEG:PCLP3 
ratio, and only for the Mal-PEG-Mal reaction (B). There, there is a significant band ~55 
kDa corresponding to the bioconjugated dimer, PCLP-PEG-PCLP (MW ~44,000). We 
are unsure why the ratio’s effect would be opposite in CCLP and PCLP. The base-
catalyzed reaction is affected by the size of the Michael donor27, and PCLP is less than 
half the size of CCLP and lacks conformation, so it is intuitive that it reacts more rapidly 
and efficiently at lower levels of PEG. This 1:2 ratio is what anticipated would be most 
effective because PCLP3 has one reactive site compared to two on Mal-PEG-Mal and 
VS-PEG-VS, so it makes sense that having double the protein and evening out the ratio 
of reactive groups would be beneficial for the bioconjugation. 
 
IV. Bioconjugation Results for CCLP Bis-Cys 
Figure 3.10 illustrates the vast potential that bioconjugation with CCLP Bis-Cys 
has. There are bands corresponding to a bioconjugated trimer, something unachievable 
with the other constructs. Additionally, there is the possibility for further modification to 
a bioconjugated tetramer or pentamer. Since there is not much resolution at the higher 
molecular weights, we would like to run another Bis-Cys reaction on a different MW 
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ladder or use MALDI to more precisely determine the extent and limits of bioconjugation 
between PEG and CCLP Bis-Cys. 
Clearly, the addition of 1 or 2 PEGs to a single CCLP happens most often, 
evidenced by the density of those bands ~55 kDa. Di-modification occurs to an 
appreciable extent as well, whereas the bands representing the trimer are less dense, but 
still substantial. This gel is an important proof-of-concept, showing that both cysteines 
are indeed reactive, and this construct has the potential to create a hydrogel by itself, as it 
can continue to lengthen indefinitely. While the CCLP3 reactions had a good proportion 
of mono-modified protomer, the CCLP3 Bis-Cys construct has a more even distribution 
of modified protein in many intermediate forms. This shows that CCLP3 Bis-Cys has the 
most potential to form a hydrogel with fine-tunable properties; modification results in a 
variety of construct lengths. Based on these results, the CCLP3 Bis-Cys construct seems 
the most promising for this type of bioconjugation reaction. We are unsure if the reason 
for this better reactivity is due simply to the increased number of thiols on the protomer, 
or if there is another underlying reason.  
The difference between Mal-PEG-Mal and VS-PEG-VS is not as apparent here; 
both conditions are able to produce the triple-CCLP construct to an appreciable extent. 
Perhaps this is because we used all the reaction conditions we had found to be favorable 
throughout the CCLP3 studies and thus overcame any barrier VS-PEG-VS had to 
reacting at the same level.  
Our results show bioconjugation of the three constructs tested. A complimentary 
method such as MALDI or HPLC is needed to quantify the data and to more accurately 
assess the results.  
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CHAPTER 5 
CONCLUSION 
The overall goal of this experiment was to explore Thiol-Michael addition 
reactions to manipulate the extent of bioconjugation between our protomers and PEG 
crosslinkers. By investigating factors that could affect the reaction, we can better 
understand how to promote the formation of longer polymers, and use this information to 
create hydrogels that have different sets of physical properties and that can be used in 
different applications. When polymers are lengthened via bioconjugation, they have 
higher degrees of entanglement which would theoretically produce a hydrogel with 
greater structural integrity. 
Generally, the results show that Thiol-Michael addition is a feasible way of 
manipulating the length and geometries of the protomers and potentially fine-tuning the 
physical properties of the hydrogel they create. In summary, 1 mM TCEP has universally 
positive effects on bioconjugation by keeping the cysteine thiols reduced, and thus 
reactive. Urea and temperature have no significant effect on the extent of bioconjugation, 
but the urea studies show that our cysteine thiols are not sterically hindered. Maleimide is 
certainly a more reactive Michael acceptor than vinyl sulfone, so that, along with its 
properties and lower preferred pH, should be taken into account when choosing a 
Michael acceptor reagent in future studies.  
The ratio of PEG:Protein had a variable effect on the reaction. For CCLP3 
constructs, an excess of PEG promoted bioconjugation. For PCLP3, the trend was 
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reversed. This ratio manipulation will be an interesting strategy for promoting the 
formation of bioconjugated dimer in future studies.  
Additionally, we saw that PCLP also has the potential to undergo this 
bioconjugation. This is positive because a hydrogel with both PCLP and CCLP 
bioconjugated dimers could have an even greater difference in physical properties. This 
modification has the added benefit of increasing the solubility of PCLP because of PEG’s 
hydrophilicity, making PCLP easier to work with in aqueous solution. 
All of the constructs are modifiable, but CCLP Bis-Cys is the most promising for 
the future. Our results showed that both cysteines are reactive with both Mal-PEG-Mal 
and VS-PEG-VS, enabling the bioconjugation of multiple CCLPs through this reaction. 
CCLP Bis-Cys has the most potential out of all of our constructs because it has more 
opportunities for bioconjugation and chain polymerization. Our results suggest that we 
could create a hydrogel entirely constructed with bioconjugated CCLP Bis-Cys. 
Throughout all of the conditions explored, we were unable to fully covert the 
unmodified protomer to bioconjugated protein. Though it varied based on the conditions, 
we were never able to convert more than ~75% of it to bioconjugated protein. Future 
reactions should explore other ways to push the formation of bioconjugated protein dimer 
so we can further impact the physical properties of the hydrogel. 
The studies explored here imply that our protomers are easily functionalized with 
PEG crosslinkers and are impacted by variables such as temperature, reducing agent, and 
the ratio of PEG:Protein. By manipulating these variables, we hypothesize that we will be 
able to use the different extents of bioconjugation to fine-tune the physical properties of 
the hydrogel, increasing its utility in a variety of applications. 
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The next step is to actually form hydrogels with these bioconjugated protomers 
and do microrheology studies to determine the tangible effect of these modifications. We 
would examine how the extent of bioconjugation impacts physical hydrogel properties 
such as elasticity and viscosity. 
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APPENDIX A – Gene design 
 
 
 
Figure A.1. Plasmid. 
(Novagen) 
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APPENDIX B – Nucleophile- versus base-catalyzed reactions 
 
Figure A.2. Modification of PCLP3 with Mal-PEG-Mal and VS-PEG-VS with both 
nucleophile- and base-catalyzed mechanisms. 
The left lane has the molecular weight standard. The next lane has PCLP3, then PCLP modified with Mal-
PEG-Mal via TEOA (base), then PCLP modified with Mal-PEG-Mal via PPY (nucleophile), then PCLP 
modified with VS-PEG-VS via TEOA (base), then PCLP modified with VS-PEG-VS via PPY 
(nucleophile).  
 
From this gel, we determined that there was no appreciable difference between using 
PPY and TEOA, so we chose to proceed with the base-catalyzed mechanism. 
Additionally, it further shows that Mal-PEG-Mal is more reactive than VS-PEG-VS.  
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APPENDIX C – Michael-addition reaction protocols 
 
Table A.1. Study A - Effect of TCEP on bioconjugation of CCLP3 and VS-PEG-VS. 
Reaction # Buffer Conc. 
TCEP 
Conc. VS-
PEG-VS 
Conc. 
CCLP3 
Temperature 
1 1 0 mM 1 mM 0.5 mM 22  
2 1 0.1 mM 1 mM 0.5 mM 22  
3 1 1 mM 1 mM 0.5 mM 22  
 
Table A.2. Study B - Effect of temp. on bioconjugation of CCLP3 and VS-PEG-VS. 
Reaction # Buffer Conc. 
TCEP 
Conc. VS-
PEG-VS 
Conc. 
CCLP3 
Temperature 
1 1 1 mM 1 mM 0.5 mM 8 
2 1 1 mM 1 mM 0.5 mM 22 
3 1 1 mM 1 mM 0.5 mM 37 
 
Table A.3. Study C - Effect of urea on bioconjugation of CCLP3 and VS-PEG-VS. 
Reaction # Buffer Conc. 
TCEP 
Conc. VS-
PEG-VS 
Conc. 
CCLP3 
Temperature 
1 1 (0 M 
Urea) 
1 mM 1 mM 0.5 mM 22 
2 2 (6 M 
Urea) 
1 mM 1 mM 0.5 mM 22 
 
Table A.4. Study D - Effect of VS-PEG-VS:CCLP3 ratio on bioconjugation. 
Reaction # Buffer Conc. 
TCEP 
Conc. VS-
PEG-VS 
Conc. 
CCLP3 
Temperature 
1 (1:1) 1 1 mM 0.5 mM 0.5 mM 22 
2 (1:2) 1 1 mM 0.25 mM 0.5 mM 22 
 
Table A.5. Study E - Effect of TCEP on bioconjugation of CCLP3 and Mal-PEG-Mal. 
Reaction # Buffer Conc. 
TCEP 
Conc. Mal-
PEG-Mal 
Conc. 
CCLP3 
Temperature 
1 3 0 mM 1 mM 0.5 mM 22 
2 3 0.1 mM 1 mM 0.5 mM 22 
3 3 1 mM 1 mM 0.5 mM 22 
 
Table A.6. Study F - Effect of temp. on bioconjugation of CCLP3 and Mal-PEG-Mal. 
Reaction # Buffer Conc. 
TCEP 
Conc. Mal-
PEG-Mal 
Conc. 
CCLP3 
Temperature 
1 3 1 mM 1 mM 0.5 mM 8 
2 3 1 mM 1 mM 0.5 mM 22 
3 3 1 mM 1 mM 0.5 mM 37 
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Table A.7. Study G - Effect of urea on bioconjugation of CCLP3 and Mal-PEG-Mal. 
Reaction # Buffer Conc. 
TCEP 
Conc. Mal-
PEG-Mal 
Conc. 
CCLP3 
Temperature 
1 3 (0 M 
urea) 
1 mM 1 mM 0.5 mM 22 
2 4 (6 M 
urea) 
1 mM 1 mM 0.5 mM 22 
 
Table A.8. Study H - Effect of Mal-PEG-Mal:CCLP3 ratio on bioconjugation. 
Reaction # Buffer Conc. 
TCEP 
Conc. Mal-
PEG-Mal 
Conc. 
CCLP3 
Temperature 
1 (1:1) 3 1 mM 0.5 mM 0.5 mM 22 
2 (1:2) 3 1 mM 0.25 mM 0.5 mM 22 
 
Table A.9. Study I – Bioconjugation of CCLP Bis-Cys with VS-PEG-VS and Mal-PEG-
Mal. 
Reaction # Buffer Conc. 
TCEP 
Conc. PEG Conc. 
CCLP Bis-
Cys 
Temperature 
1 1 1 mM 1 mM VS-
PEG-VS 
0.5 mM 37 
2 3 1 mM 1 mM Mal-
PEG-Mal 
0.5 mM 37 
 
Table A.10. Study J – PCLP3 Bioconjugation with VS-PEG-VS.  
Reaction # Buffer Conc. 
TCEP 
Conc. VS-
PEG-VS 
Conc. 
PCLP3 
Temperature 
1 (2:1) 2 1 mM 0.2 mM 0.1 mM 37 
2 (1:1) 2 1 mM 0.1 mM 0.1 mM 37 
3 (1:2) 2 1 mM 0.05 mM 0.1 mM 37 
 
Table A.11. Study K – PCLP3 Bioconjugation with Mal-PEG-Mal.  
Reaction # Buffer Conc. 
TCEP 
Conc. Mal-
PEG-Mal 
Conc. 
PCLP3 
Temperature 
1 (2:1) 4 1 mM 0.2 mM 0.1 mM 37 
2 (1:1) 4 1 mM 0.1 mM 0.1 mM 37 
3 (1:2) 4 1 mM 0.05 mM 0.1 mM 37 
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Appendix D – Structure and properties of additional chemicals used 
 
Table A.12. Structure, function, and molecular weight of additional chemicals. 
Name Structure Function MW 
Triethanolamine 
(TEOA) 
 
 
Base 149.18 
g/mol 
Tris(2-carboxyethyl) 
phosphine (TCEP) 
 
Reducing 
agent 
286.65 
g/mol 
Dithiothreitol (DTT) 
 
 
Reducing 
agent 
154.24 
g/mol 
 
 
 
 
 
 
 
 
 
 
 
 
 
